FDA Approves Tauklarify (florquinitau F 18 injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease
RegulatoryapprovedTauklarifyPositive
AI Analysis
Summary
Lantheus Holdings' Tauklarify (florquinitau F 18 injection), an F18-labeled tau PET imaging agent, has received FDA approval for Alzheimer's Disease. The approval marks a significant milestone for the radiopharmaceutical company's diagnostic imaging portfolio.
Outcome Details
FDA approval of Tauklarify (florquinitau F 18 injection) for Alzheimer's Disease
Importance:8/10
Sentiment:
0.90
FDA ApprovalRadiopharmaceuticalAlzheimer's DiseasePET ImagingLantheus
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on August 14, 2026 8:08 PM